Immune Thrombocytopenia (ITP) Clinical Trials

28 recruitingLast updated: May 21, 2026

There are 28 actively recruiting immune thrombocytopenia (itp) clinical trials across 29 countries. Studies span Phase 2, Phase 3, Phase 1, Early Phase 1, Not Applicable, Phase 4. Top locations include Tianjin, Tianjin Municipality, China, Beijing, Beijing Municipality, China, Créteil, France. Updated daily from ClinicalTrials.gov.


Immune Thrombocytopenia (ITP) Trials at a Glance

28 actively recruiting trials for immune thrombocytopenia (itp) are listed on ClinicalTrialsFinder across 6 cities in 29 countries. The largest study group is Phase 2 with 12 trials, with the heaviest enrollment activity in Tianjin, Beijing, and Créteil. Lead sponsors running immune thrombocytopenia (itp) studies include Institute of Hematology & Blood Diseases Hospital, China, Assistance Publique - Hôpitaux de Paris, and argenx.

Browse immune thrombocytopenia (itp) trials by phase

About Immune Thrombocytopenia (ITP) Clinical Trials

Looking for clinical trials for Immune Thrombocytopenia (ITP)? There are currently 15 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Immune Thrombocytopenia (ITP) trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Immune Thrombocytopenia (ITP) clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 28 trials

Recruiting
Phase 1Phase 2

A Study of Pirtobrutinib in Participants With Immune Thrombocytopenia

Immune Thrombocytopenia (ITP)
Eli Lilly and Company58 enrolled45 locationsNCT06721013
Recruiting
Phase 2

A Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in Patients With Primary Immune Thrombocytopenia (ITP)

Primary Immune Thrombocytopenia (ITP)Primary Evans Syndrome (ES)
Novartis Pharmaceuticals164 enrolled2 locationsNCT07421167
Recruiting
Phase 3

A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia

Primary Immune Thrombocytopenia (ITP)
argenx69 enrolled94 locationsNCT06544499
Recruiting
Phase 4

Eltrombopag Combining Rituximab Versus Eltrombopag in the Management of Primary Immune Thrombocytopenia (ITP) in Adults

Primary Immune Thrombocytopenia (ITP)
Institute of Hematology & Blood Diseases Hospital, China224 enrolled1 locationNCT04518475
Recruiting
Phase 3

High-Dose Dexamethasone Combined With Orelabrutinib Versus High-Dose Dexamethasone Combined With Placebo in Adult Patients With Newly Diagnosed Primary Immune Thrombocytopenia

Primary Immune Thrombocytopenia (ITP)
Shandong University86 enrolled1 locationNCT07559331
Recruiting
Phase 2Phase 3

A Study of Efgartigimod IV in Participants From 12 Years to Less Than 18 Years of Age With Chronic Immune Thrombocytopenia (ITP)

Immune Thrombocytopenic PurpuraITPIdiopathic Thrombocytopenic Purpura+4 more
argenx24 enrolled8 locationsNCT07194850
Recruiting
Phase 3

An Open-label Study of Intravenous Immunoglobulin (5%) for the Treatment of Primary Immune Thrombocytopenia

Primary Immune Thrombocytopenia (ITP)
Grand Shuyang Life Sciences (Chengdu) Co., Ltd.36 enrolled9 locationsNCT07233213
Recruiting
Phase 1

Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)

Antiphospholipid Syndrome (APS)Immune-mediated Necrotizing Myopathy (IMNM)Immune Thrombocytopenia (ITP)+3 more
Chugai Pharmaceutical144 enrolled69 locationsNCT06371417
Recruiting
Phase 1Phase 2

A Phase 1b/2a Study of Budoprutug in Subjects With Immune Thrombocytopenia (ITP)

ITPImmune Thrombocytopenia (ITP)Monoclonal+2 more
Climb Bio, Inc.24 enrolled20 locationsNCT07043946
Recruiting
Phase 3

A Study Investigating Intravenous Human Normal Immunoglobulin 10% in Adults With Chronic Immune Thrombocytopenia (ITP)

Chronic Primary Immune Thrombocytopenia (ITP)
Kedrion S.p.A.40 enrolled27 locationsNCT07059000
Recruiting
Phase 1

Study of PN20 in Adult Patients With Primary Immune Thrombocytopenia (ITP)

Primary Immune Thrombocytopenia (ITP)
Chongqing Peg-Bio Biopharm Co., Ltd.12 enrolled5 locationsNCT06880081
Recruiting
Phase 2

A Study of DZD8586 in Adults With Primary Immune Thrombocytopenia (ITP) (TAI-SHAN11)

Immune Thrombocytopenia (ITP)
Dizal Pharmaceuticals60 enrolled1 locationNCT07294365
Recruiting
Phase 3

V-IMMUNE® for Immune Thrombocytopenia

Immune Thrombocytopenia (ITP)
On Pharma Importadora, Exportadora e Distribuidora de Medicamentos LTDA.31 enrolled2 locationsNCT06962631
Recruiting
Phase 1Phase 2

A Phase Ib/II Clinical Trial of Multiple Doses of STSA-1301 Subcutaneous Injection in Healthy Subjects and Patients With Immune Thrombocytopenia (ITP)

Primary Immune Thrombocytopenia (ITP)
Jiangsu BioJeTay Biotechnology Co., Ltd.56 enrolled7 locationsNCT06929299
Recruiting
Phase 1Phase 2

A Study of CM336 in Patients With Relapsed or Refractory Autoimmune Cytopenia

Autoimmune Hemolytic AnemiaEvans SyndromeAutoimmune Cytopenia+1 more
Keymed Biosciences Co.Ltd158 enrolled3 locationsNCT07175493
Recruiting
Early Phase 1

An Exploratory Study of CD19/CD22/BCMA CAR-T Cells (BZE2204) in Subjects With Relapsed or Refractory Autoimmune Diseases

Systemic Lupus Erythematosus (SLE)Immune Thrombocytopenia (ITP)Idiopathic Inflammatory Myopathies(IIM)
Shanghai Cell Therapy Group Co.,Ltd20 enrolled1 locationNCT07174843
Recruiting
Early Phase 1

Safety Study of CC312 in Autoimmune Disease Patients

Rheumatoid Arthritis (RA)Autoimmune Hemolytic AnemiaSystemic Lupus Erythematosus (SLE)+3 more
CytoCares Inc18 enrolled1 locationNCT06888960
Recruiting
Phase 2

The Efficacy and Safety of Combined Teriflunomide and High-dose Dexamethasone in Newly Diagnosed Primary Immune Thrombocytopenia (TEMPO-2)

Immune Thrombocytopenia (ITP)
Peking University People's Hospital132 enrolled3 locationsNCT07065968
Recruiting
Not Applicable

Anti CD19/BCMA CAR Gene Therapy for Relapsed/Refractory Immune Thrombocytopenia

Immune Thrombocytopenia (ITP)
Anhui Provincial Hospital18 enrolled1 locationNCT06973356
Recruiting
Phase 2

Safety, Tolerability, and Efficacy of NVG-2089 in Participants With Immune Thrombocytopenia

Immune Thrombocytopenia (ITP)
Nuvig Therapeutics, Inc.10 enrolled1 locationNCT07095127